Literature DB >> 1149212

Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

C A Chidsey, P Morselli, G Bianchetti, A Morganti, G Leonetti, A Zanchetti.   

Abstract

The variability of plasma propranolol concentrations has been determined in a large group of patients being treated with the drug. Although the average patient achieved a therapeutic plasma level with 160 mg/day, there was marked interpatient variation. This was found to be primarily the result of differences in effective absorption of the drug, which averaged 46% of the oral dose but ranged from 20 to 80%. Propranolol disappeared from plasma with a half-life of 4.7 hours and its removal appeared to follow dose independent kinetics with no evidence of saturation of hepatic metabolism. The derived pharmacokinetic values of volume of distribution and clearance rate have been used to provide guidelines for initiating propranolol therapy intravenously, and the schedule of 8 mg as a loading dose and 0.02 mg/min as a sustaining dose has been suggested.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1149212     DOI: 10.1161/01.cir.52.2.313

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Hypertension: which beta-blocker?

Authors:  H J Waal-Manning
Journal:  Drugs       Date:  1976-12       Impact factor: 9.546

2.  Improved fluorimetric assay of plasma propranolol.

Authors:  L Offerhaus; J R van der Vecht
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

3.  Bioavailability of beta-adrenoceptor blocking drugs.

Authors:  G Johnsson; C G Regardh
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

4.  Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.

Authors:  R Lapka; T Sechser; V Rejholec; M Peterková; M Votavová
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Pharmacokinetics of propranolol in normal healthy volunteers.

Authors:  R Gomeni; G Bianchetti; R Sega; P L Morselli
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

6.  Clinical pharmacology of a new beta-adrenoceptor blocking drug, befunolol. Cross-over comparison with propranolol on repeated administration.

Authors:  A Ebihara; K Tawara; T Oka; T Ofuji; K Kawahara
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  Plasma concentrations of propranolol and 4-hydroxypropranolol during chronic oral propranolol therapy.

Authors:  L Wong; R L Nation; W L Chiou; P K Mehta
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

8.  Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.

Authors:  N Himori; S Honma; A Izumi; T Ishimori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

9.  Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.

Authors:  D P Nicholls; D W Harron; J McAinsh; W M Castle; N P Barker; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

10.  The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients.

Authors:  R Zain-Hamid; Z Ismail; S Mahendra Raj; I L Shuaib; S S J Mohsin
Journal:  Malays J Med Sci       Date:  2002-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.